856 related articles for article (PubMed ID: 33188775)
1. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.
Wesseling H; Mair W; Kumar M; Schlaffner CN; Tang S; Beerepoot P; Fatou B; Guise AJ; Cheng L; Takeda S; Muntel J; Rotunno MS; Dujardin S; Davies P; Kosik KS; Miller BL; Berretta S; Hedreen JC; Grinberg LT; Seeley WW; Hyman BT; Steen H; Steen JA
Cell; 2020 Dec; 183(6):1699-1713.e13. PubMed ID: 33188775
[TBL] [Abstract][Full Text] [Related]
2. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
Haj-Yahya M; Lashuel HA
J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
[TBL] [Abstract][Full Text] [Related]
3. Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation.
Acosta DM; Mancinelli C; Bracken C; Eliezer D
J Biol Chem; 2022 Jan; 298(1):101442. PubMed ID: 34838590
[TBL] [Abstract][Full Text] [Related]
4. FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.
Mair W; Muntel J; Tepper K; Tang S; Biernat J; Seeley WW; Kosik KS; Mandelkow E; Steen H; Steen JA
Anal Chem; 2016 Apr; 88(7):3704-14. PubMed ID: 26877193
[TBL] [Abstract][Full Text] [Related]
5. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Methylation and Phosphorylation Stoichiometry.
Ayoub CA; Moore KI; Kuret J
Methods Mol Biol; 2024; 2754():221-235. PubMed ID: 38512670
[TBL] [Abstract][Full Text] [Related]
7. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
Thomas SN; Yang AJ
Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
[TBL] [Abstract][Full Text] [Related]
8. Role of Post-translational Modifications in Alzheimer's Disease.
Ramesh M; Gopinath P; Govindaraju T
Chembiochem; 2020 Apr; 21(8):1052-1079. PubMed ID: 31863723
[TBL] [Abstract][Full Text] [Related]
9. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry.
Kelley AR; Bach SBH; Perry G
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2040-2047. PubMed ID: 30481587
[TBL] [Abstract][Full Text] [Related]
10. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease.
Balmik AA; Chinnathambi S
Cell Commun Signal; 2021 May; 19(1):51. PubMed ID: 33962636
[TBL] [Abstract][Full Text] [Related]
11. SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer's disease.
Bichmann M; Prat Oriol N; Ercan-Herbst E; Schöndorf DC; Gomez Ramos B; Schwärzler V; Neu M; Schlüter A; Wang X; Jin L; Hu C; Tian Y; Ried JS; Haberkant P; Gasparini L; Ehrnhoefer DE
Mol Neurodegener; 2021 Jul; 16(1):46. PubMed ID: 34215303
[TBL] [Abstract][Full Text] [Related]
12. Distinct tau folds initiate templated seeding and alter the post-translational modification profile.
Tarutani A; Kametani F; Tahira M; Saito Y; Yoshida M; Robinson AC; Mann DMA; Murayama S; Tomita T; Hasegawa M
Brain; 2023 Dec; 146(12):4988-4999. PubMed ID: 37904205
[TBL] [Abstract][Full Text] [Related]
13. Tau seeds are subject to aberrant modifications resulting in distinct signatures.
Tseng JH; Ajit A; Tabassum Z; Patel N; Tian X; Chen Y; Prevatte AW; Ling K; Rigo F; Meeker RB; Herring LE; Cohen TJ
Cell Rep; 2021 Apr; 35(4):109037. PubMed ID: 33910013
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer's Disease.
Huseby CJ; Hoffman CN; Cooper GL; Cocuron JC; Alonso AP; Thomas SN; Yang AJ; Kuret J
J Alzheimers Dis; 2019; 71(3):979-991. PubMed ID: 31450505
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease.
Abreha MH; Dammer EB; Ping L; Zhang T; Duong DM; Gearing M; Lah JJ; Levey AI; Seyfried NT
Proteomics; 2018 Oct; 18(20):e1800108. PubMed ID: 30230243
[TBL] [Abstract][Full Text] [Related]
16. A validated antibody panel for the characterization of tau post-translational modifications.
Ercan E; Eid S; Weber C; Kowalski A; Bichmann M; Behrendt A; Matthes F; Krauss S; Reinhardt P; Fulle S; Ehrnhoefer DE
Mol Neurodegener; 2017 Nov; 12(1):87. PubMed ID: 29157277
[TBL] [Abstract][Full Text] [Related]
17. JUMPptm: Integrated software for sensitive identification of post-translational modifications and its application in Alzheimer's disease study.
Poudel S; Vanderwall D; Yuan ZF; Wu Z; Peng J; Li Y
Proteomics; 2023 Feb; 23(3-4):e2100369. PubMed ID: 36094355
[TBL] [Abstract][Full Text] [Related]
18. Degradation or aggregation: the ramifications of post-translational modifications on tau.
Park S; Lee JH; Jeon JH; Lee MJ
BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
[TBL] [Abstract][Full Text] [Related]
19. Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis.
Sonawane SK; Chinnathambi S
J Mol Neurosci; 2018 Aug; 65(4):480-490. PubMed ID: 29982964
[TBL] [Abstract][Full Text] [Related]
20. Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls.
Ayyadevara S; Balasubramaniam M; Parcon PA; Barger SW; Griffin WS; Alla R; Tackett AJ; Mackintosh SG; Petricoin E; Zhou W; Shmookler Reis RJ
Aging Cell; 2016 Oct; 15(5):924-39. PubMed ID: 27448508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
